Table 1.
Baseline demographic and psychiatric characteristics (Safety Set)
| Variables | Single administration study | Multiple administration study | |
|---|---|---|---|
|
Aripiprazole IMD 300 mg (N = 12) |
Aripiprazole IMD 400 mg (N = 12) |
(N = 12) | |
| Sex male | |||
| n (%) | 11 (91.7) | 11 (91.7) | 11 (91.7) |
| Race, Han nationality | |||
| n (%) | 12 (100) | 10 (83.3) | 11 (91.7) |
| Age, years | |||
| mean (SD) | 41.3 (12.48) | 35.3 (13.21) | 32.4 (6.30) |
| BMI, kg/m2 | |||
| mean (SD) | 26.53 (3.22) | 24.38 (4.51) | 23.91 (4.14) |
| Baseline disease characteristics | |||
| Age at first diagnosis of schizophrenia (years), mean (SD) | 29.3 (10.46) | 27.1 (9.39) | 32.4(6.30) |
| PANSS total score, mean (SD) | 73.3 (10.4) | 80.0 (8.2) | 65.5 (14.5) |
| CGI-S score, mean (SD) | 4.6 (1.0) | 5.0 (0.7) | 3.9 (0.9) |
SD standard deviation, BMI body mass index, PANSS Positive and Negative Syndrome Scale, CGI-S Clinical Global Impressions-Severity